News | July 09, 2010

Gore Hopeful for Positive PFO Occluder Trial Data

July 9, 2010 – W. L. Gore and Associates announced today that they are confident in the design and anticipated results of the Gore REDUCE Clinical Study, which was designed to test the safety and effectiveness of the Gore Helex Septal Occluder for patent foramen ovale (PFO) closure in patients with history of cryptogenic stroke or imaging-confirmed transient ischemic attack (TIA). This prospective and randomized trial, which includes up to 50 investigational sites in the United States, Denmark, Finland, Norway and Sweden, is on track to be completed in 2015.

Stuart Broyles, Ph.D., associate with the Gore medical division stroke business, said that in light of the recent press release regarding the preliminary results of CLOSURE I, Gore officials wanted to re-emphasize their confidence in the design and expected outcome of the Gore REDUCE Clinical Study.

“Due to our European experience regarding the clinical performance of the GORE HELEX Septal Occluder and our unique study design, we remain very confident that the Gore REDUCE Clinical Study will ultimately achieve its intended objective,” Broyles said. “We are committed to the completion of this study and the pursuit of an FDA indication for PFO closure and the prevention of recurrent stroke.”

Scott Kasner, M.D., professor of neurology and director of the Comprehensive Stroke Center at the University of Pennsylvania Medical Center, and U.S. neurology principal investigator, said there are several aspects that make the design of the Gore REDUCE Clinical Study unique from the other PFO stroke trials.

“First, magnetic resonance imaging (MRI) of the brain will be performed on all patients at baseline and at two years. This feature offers an additional imaging endpoint for making comparisons between the treatment arms,” Kasner said. “Second, it focuses on secondary prevention of stroke rather than TIA, which improves the reliability of the study outcomes and measurably impacts the public health. Finally, this is a multinational study, which enhances its global applicability.”

Kasner went on to say these efforts will likely help resolve the question of whether PFO closure is a viable alternative for treating cryptogenic stroke/TIA patients as compared to medical treatment alone.

Other features of the Gore REDUCE Clinical Study include:
• Participation of Nordic investigational sites, which is projected to help drive study enrollment;
• The use of imaging-confirmed stroke / TIA for assessing its primary endpoint;
• A 2:1 device to medical management randomization strategy;
• A standardization of medical therapies across treatment arms; and
• The use of the GORE HELEX Septal Occluder, which was approved by the U.S. Food and Drug Administration (FDA) in 2007 for treatment of atrial septal defect (ASD), a congenital heart defect.

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp